Takeda Gets FDA Nod For HyQvia In CIDP
The drug could become competitive with Argenx’s Vyvgart Hytrulo, but the market opportunity for the rare disease remains unclear due to continued diagnostic challenges.
The drug could become competitive with Argenx’s Vyvgart Hytrulo, but the market opportunity for the rare disease remains unclear due to continued diagnostic challenges.